The treatment by expanded ex vivo autologous regulatory T-cells CD4+CD25+FoxP3+CD127low restores the balance of immune system in patients with remitting-relapsing multiple sclerosis

Eliseeva D.D.; Lifshitz G.V.; Lokhonina A.V.; Zhdanov D.D.; Zavalishin I.A.; Bykovskaia S.N.

doi:https://doi.org/10.17116/jnevro20161162254-62

Eliseeva D.D.

Kafedra akusherstva i ginekologii im. S.S. Dobrotina Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Lifshitz G.V.

Pirogov Russian National Research Medical University, Moscow

Lokhonina A.V.

Pirogov Russian National Research Medical University, Moscow;
Regenex LLC, Skolkovo Innovation Center, Moscow

Zhdanov D.D.

Pirogov Russian National Research Medical University, Moscow;
Regenex LLC, Skolkovo Innovation Center, Moscow

Zavalishin I.A.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Bykovskaia S.N.

Otdel kletochnykh tekhnologiĭ i regenerativnoĭ meditsiny Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

The treatment by expanded ex vivo autologous regulatory T-cells CD4+CD25+FoxP3+CD127low restores the balance of immune system in patients with remitting-relapsing multiple sclerosis

Authors:

Eliseeva D.D., Lifshitz G.V., Lokhonina A.V., Zhdanov D.D., Zavalishin I.A., Bykovskaia S.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2‑2): 54‑62

DOI: 10.17116/jnevro20161162254-62

Read: 1518 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Eliseeva DD, Lifshitz GV, Lokhonina AV, Zhdanov DD, Zavalishin IA, Bykovskaia SN. The treatment by expanded ex vivo autologous regulatory T-cells CD4+CD25+FoxP3+CD127low restores the balance of immune system in patients with remitting-relapsing multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2‑2):54‑62. (In Russ.)
https://doi.org/10.17116/jnevro20161162254-62

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective. To assess clinical efficacy and safety of the autologous (own) regulatory T-cells (Tregs)CD4+CD25+Foxp3+CD127low isolated from the blood of patients with remitting-relapsing multiple sclerosis. Patients with autoimmune diseases have the decreased number of peripheral Tregs (pTreg) and impaired suppressive ability. In order to restore levels of pTreg, it is possible to isolate precursor cells, enter expanded ex vivo autologous Treg cells and introduce an expanded amount of autologous cells as Treg vaccine. Material and methods. A method of ex vivo Tregs expansion by 30—40 times within 5—7 days has been developed. Expanded ex vivo Tregs are more than 90% CD4+CD25+Foxp3+CD127low and have high suppressor activity. Fourteen patients with remitting-relapsing multiple sclerosis were included in pilot studies.Ex vivoTregs were introduced subcutaneously in dosefrom 2.8 to 4.5 108 cell per injection. The duration of follow-up was 1 year. Results and conclusion. The numbers of pTregs in the blood of these patients elevated by 1.5—2 times. No adverse-effects, a decrease of relapses and stabilization of disability index were observed. It has been suggested that ex vivo expanded Tregs can compensate the impaired function of pTregs and can be used for adoptive immunotherapyof multiple sclerosis.

Keywords:

remitting-relapsing multiple sclerosis

T-regulatory cells

adoptive immunotherapy

immune balance

Authors:

Eliseeva D.D.

Kafedra akusherstva i ginekologii im. S.S. Dobrotina Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Lifshitz G.V.

Pirogov Russian National Research Medical University, Moscow

Lokhonina A.V.

Pirogov Russian National Research Medical University, Moscow;
Regenex LLC, Skolkovo Innovation Center, Moscow

Zhdanov D.D.

Pirogov Russian National Research Medical University, Moscow;
Regenex LLC, Skolkovo Innovation Center, Moscow

Zavalishin I.A.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Bykovskaia S.N.

Otdel kletochnykh tekhnologiĭ i regenerativnoĭ meditsiny Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

Close metadata

References:

Crispin J, Alcocer-Varela J, de Pablo P, Martínez A, Richaud-Patin Y, Alarcón-Segovia D. Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission. Lupus. 2003;12(5):386-393. doi: 10.1191/0961203303lu368oa.
Kukreja A, Cost G, Marker J et al. Multiple mmune-regulatory defects in type-1 diabetes. Journal of Clinical Investigation. 2002;109(1):131-140. doi: 10.1172/jci200213605.
de Kleer I, Wedderburn L, Taams L et al. CD4⁺CD25bright Regulatory T Cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis. The Journal of Immunology. 2004;172(10):6435-6443. doi: 10.4049/jimmunol.172.10.6435.
Valencia X, Yarboro C, Illei G, Lipsky P. Deficient CD4⁺CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus. The Journal of Immunology. 2007;178(4):2579-2588. doi: 10.4049/jimmunol.178.4.2579.
Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced number and function of CD4⁺CD25highFoxP3⁺ regulatory T cells in patients with systemic lupus erythematosus. Advances in experimental medicine and biology. 2007;601:113-119. http://www.ncbi.nlm.nih.gov/pubmed/17712998.
Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med. 2010;16(2):58-68. doi: 10.1016/j.molmed.2009.12.003.
Buckner J. Mechanisms of impaired regulation by CD4⁺CD25⁺FOXP3⁺ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12):849-859. doi: 10.1038/nri2889.
Gambineri E, Torgerson T, Ochs H. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Current Opinion in Rheumatology. 2003;15(4):430-435. doi: 10.1097/00002281-200307000-00010.
Fontenot J, Gavin M, Rudensky A. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nature Immunology. 2003;4(4):330-336. doi: 10.1038/ni904.
Liu W. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4⁺ T reg cells. Journal of Experimental Medicine. 2006;203(7):1701-1711. doi:10.1084/jem.20060772.
Seddiki N. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. Journal of Experimental Medicine. 2006;203(7):1693-1700. doi:10.1084/jem.20060468.
Hartigan-O’Connor D, Poon C, Sinclair E, McCune J. Human CD4⁺ regulatory T cells express ^lower levels of the IL-7 receptor alpha chain (CD127), al^lowing consistent identification and sorting of live cells. Journal of Immunological Methods. 2007;319(1-2):41-52. doi:10.1016/j.jim.2006.10.008.
Yadav M, Stephan S, Bluestone J. Peripherally Induced Tregs — Role in Immune Homeostasis and Autoimmunity. Front Immunol. 2013;4. doi:10.3389/fimmu.2013.00232.
Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3⁺ regulatory T cells in systemic autoimmune diseases. Autoimmunity Reviews. 2011;10(12):744-755. doi:10.1016/j.autrev.2011.05.004.
Hoffmann P. Large-scale in vitro expansion of polyclonal human CD4⁺CD25high regulatory T cells. Blood. 2004;104(3):895-903. doi:10.1182/blood-2004-01-0086.
Eliseeva D.D., Zavalishin I.A., Karaulov A.V., Bykovskaya S.N. Rol' regulyatornykh T-kletok v razvitii autoimmunnykh narushenii pri rasseyannom skleroze. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2012;(3):68-74. http://www.ncbi.nlm.nih.gov/pubmed/22712278
Eliseeva D.D., Zavalishin I.A., Bykovskaya S.N., Fedorova T.N., Karandashov E.N., Trunova O.A. Regulyatornye T-kletki CD4+ CD25+Foxr3+ u bol'nykh remitiruyushchim rasseyannym sklerozom. Annaly klinicheskoi i eksperimental'noi nevrologii. 2011;5(2):9-13.
Polman C, Reingold S, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302. doi:10.1002/ana.22366.
Khoury S, Guttmann C, Orav E, Kikinis R, Jolesz F, Weiner H. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 2000;57(8):1183.
Viglietta V. Loss of Functional Suppression by CD4⁺CD25⁺ Regulatory T cells in patients with multiple sclerosis. Journal of Experimental Medicine. 2004;199(7):971-979. doi:10.1084/jem.20031579.
Haas J, Maas-Enriquez M, Hartung H. Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis — results of a retrospective multicenter observational study over five years. Multiple Sclerosis. 2005;11(5):562-567. doi:10.1191/1352458505ms1224oa.
Ukena S, Höpting M, Velaga S et al. Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. Experimental Hematology. 2011;39(12):1152-1160. doi:10.1016/j.exphem.2011.08.010.
Mottet C, Uhlig H, Powrie F. Cutting Edge: Cure of Colitis by CD4⁺CD25⁺ regulatory T cells.The Journal of Immunology. 2003;170(8):3939-3943. doi:10.4049/jimmunol.170.8.3939.
Tang Q, Boden E, Henriksen K, Bour-Jordan H, Bi M, Bluestone J. Distinct roles of CTLA-4 and TGF-? in CD4⁺CD25⁺ regulatory Tcell function. European Journal of Immunology. 2004;34(11):2996-3005. doi:10.1002/eji.200425143.
Kohm A, Carpentier P, Anger H, Miller S. Cutting edge: CD4⁺CD25⁺ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. The Journal of Immunology. 2002;169(9):4712-4716. doi:10.4049/jimmunol.169.9.4712.
Morgan M, Flierman R, van Duivenvoorde L et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25⁺ regulatory T cells. Arthritis Rheum. 2005;52(7):2212-2221. doi:10.1002/art.21195.
Schneidawind D, Pierini A, Alvarez M et al. CD4⁺ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4⁺CD25⁺FoxP3⁺ regulatory T cells. Blood. 2014;124(22):3320-3328. doi:10.1182/blood-2014-05-576017.
Jones N, Turvey S, Van Maurik A et al. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. The Journal of Immunology. 2001;166(4):2824-2830. doi:10.4049/jimmunol.166.4.2824.